N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial

Arancini, Lauren, Bortolasci, Chiara C., Dodd, Seetal, Dean, Olivia M. and Berk, Michael 2019, N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial, Trials, vol. 20, pp. 1-7, doi: 10.1186/s13063-019-3628-5.

Attached Files
Name Description MIMEType Size Downloads

Title N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial
Author(s) Arancini, LaurenORCID iD for Arancini, Lauren orcid.org/0000-0002-0794-6363
Bortolasci, Chiara C.ORCID iD for Bortolasci, Chiara C. orcid.org/0000-0002-7918-4636
Dodd, SeetalORCID iD for Dodd, Seetal orcid.org/0000-0002-7918-4636
Dean, Olivia M.ORCID iD for Dean, Olivia M. orcid.org/0000-0002-2776-3935
Berk, MichaelORCID iD for Berk, Michael orcid.org/0000-0002-5554-6946
Journal name Trials
Volume number 20
Article ID 555
Start page 1
End page 7
Total pages 7
Publisher BMC
Place of publication London, Eng.
Publication date 2019-09
ISSN 1745-6215
Keyword(s) Science & Technology
Life Sciences & Biomedicine
Medicine, Research & Experimental
Research & Experimental Medicine
Smoking cessation
Summary Background: Tobacco smoking is a highly prevalent, addictive behaviour and a key public health priority. However available cessation therapies have low quit and high relapse rates, indicating an urgent need for more effective treatments. Predicated on promising preclinical and pilot clinical data, this paper presents a rationale and protocol for the trial of N-acetylcysteine (NAC) as a novel anti-craving smoking cessation aid. Methods: Current smokers (n = 120) of at least 10 cigarettes a day are recruited through online advertisements, print publications and dissemination of flyers. Participants are randomised on a 1:1 ratio to receive either 16-week treatment of 1.8 g/day of NAC or placebo with all participants receiving quit support from the online QuitCoach tool. Participants are attending visits at baseline, 8 and 16 weeks with a 42-week post-discontinuation follow-up. The primary outcome measure is sustained abstinence at six months after treatment based on self-reported rating scales and confirmed by exhaled carbon monoxide and salivary cotinine levels. Secondary outcomes are timing of the first lapse and relapse, between-group cigarette consumption, withdrawal symptoms, general wellbeing and mood/anxiety symptoms. Between-group differences in adverse events and subgroup analyses for variables including gender and Diagnostic Statistics Manual 5 diagnostics will also be investigated. Discussion: The planned trial addresses an issue of major importance to human health and, if an effect is shown, may result in substantial changes to the management of smoking and nicotine addiction with overt public health implications. Trial registration: Australian New Zealand Clinical Trials registry (ANZCTR), ACTRN12617001478303. Registered on 19 October 2017.
Language eng
DOI 10.1186/s13063-019-3628-5
Indigenous content off
Field of Research 1102 Cardiorespiratory Medicine and Haematology
1103 Clinical Sciences
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2019, The Author(s)
Persistent URL http://hdl.handle.net/10536/DRO/DU:30129719

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Open Access Checking
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 6 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Fri, 13 Sep 2019, 14:35:22 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.